{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:15:33Z","timestamp":1785161733663,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Regulatory bodies have recently approved chimeric antigen receptor (CAR)-T cell therapies for patients with multiple myeloma (MM), but the treatment process involves complex decision making. To support the introduction of these therapies, we aimed to establish consensus expert opinion on best practices of all aspects of the management of patients with MM undergoing CAR-T cell therapy in Australia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a modified RAND\/UCLA two-round Delphi panel informed by a systematic literature review (SLR). The SLR included evidence from clinical practice guidelines, interventional trials, and observational studies for CAR-T cell therapy for patients with MM, to synthesize methodological aspects of CAR-T cell therapy related to patient management. The Delphi panel comprised eight hematologists from across Australia, each with significant experience directly treating patients using CAR-T therapy or referring patients for CAR-T cell therapy. Panelists completed the surveys electronically, and attended a virtual meeting held before the second-round questionnaire to discuss the first-round questionnaire responses. Consensus was defined <jats:italic>a priori<\/jats:italic> as at least 70% agreement on survey questions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The SLR identified 22 interventional or observational studies and 5 clinical practice guidelines reporting on selection and management of patients with MM treated with CAR-T cell therapy from various global regions. The Delphi panel reached consensus on practices related to patient referral, screening, selection, prioritization, treatments requiring wash-out, bridging therapy, lymphodepletion, infusion, and post-infusion monitoring and management. Most consensus results aligned with consistently recommended practices within guidelines included in the SLR. Consensus was not reached for statements related to specific screening practices and post-treatment monitoring, suggesting differing opinions on the specific best practices to implement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our Delphi panel established expert consensus on key considerations for patient selection, administrative processes, and aftercare for patients with MM in Australia undergoing CAR-T therapy. This will guide the development of clinical practice guidelines which are relevant and feasible to Australian health systems.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1535869","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:38:31Z","timestamp":1737448711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia"],"prefix":"10.3389","volume":"14","author":[{"given":"P. Joy","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hasib","family":"Sidiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Micklethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa","family":"Cusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bagnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"B1","unstructured":"Multiple Myeloma in Australia Statistics\n          \n          Cancer Australia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med J Aust"},{"key":"B3","unstructured":"Medical Scientific Advisory Group (MSAG) to Myeloma Australia (MA) clinical practice guideline: multiple myeloma\n          \n          \n            \n              Quach\n              H\n            \n            \n              Harrison S\n              H\n            \n          \n          \n          2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood-2021-146060","article-title":"Updated results from CARTITUDE-1: Phase 1b\/2 study of ciltacabtagene autoleucel, a B-Cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"key":"B5","unstructured":"Summary for ARTG Entry: 410143 Cellular Therapies - T cells-Ciltacabtagene autoleucel, cryopreserved-T-CARVYKTI - Janssen-Cilag Pty Ltd - Injection, intravenous infusion - Bag\n          \n          \n          \n          2024"},{"key":"B6","unstructured":"Ciltacabtagene Autoleucel and Idecabtagene Vicleucel Approved by the FDA for Pretreated Patients with Multiple Myeloma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","unstructured":"CAR T-cell therapy: Is Australia ready, willing and able? Making next-generation treatments accessible to Australian patients with multiple myeloma\n          \n          \n            \n              Beardmore\n              R\n            \n            \n              Musgrave\n              S\n            \n            \n              Birchall\n              L\n            \n            \n              Stanley\n              R\n            \n            \n              Sharma\n              Y\n            \n          \n          Canberra, Australia\n          Evohealth\n          \n          2023"},{"key":"B9","unstructured":"CAR T-cell therapy a guide for patients, carers and families\n          \n          \n            \n              O\u2019Leary\n              N\n            \n            \n              Marino\n              P\n            \n          \n          Victoria, Australia\n          Peter MacCallum Cancer Centre\n          \n          2021"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000734","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/9781119536604.ch3","article-title":"Defining the criteria for including studies and how they will be grouped for the synthesis","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"McKenzie","year":"2019"},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J Healthc Leadersh"},{"key":"B14","unstructured":"The RAND\/UCLA Appropriateness Method User\u2019s Manual\n          \n          \n            \n              Fitch\n              K\n            \n            \n              Bernstein\n              SJ\n            \n            \n              Aguilar\n              MD\n            \n            \n              Burnand\n              B\n            \n            \n              LaCalle\n              JR\n            \n            \n              Lazaro\n              P\n            \n          \n          RAND Corporation\n          \n          2001"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jclinepi.2019.03.011","article-title":"Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection","volume":"111","author":"De Meyer","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2022.04.001","article-title":"The Chinese consensus for the CAR-T cell therapy in multiple myeloma (2022 version)","volume":"43","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2022.08.002","article-title":"CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil","volume":"45","author":"Hungria","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00690","article-title":"open-label study of ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor\u2013T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153796","article-title":"Real-world applicability of commercial chimeric antigen receptor T cell therapy among older adults with relapsed and\/or refractory multiple myeloma","volume":"138","author":"Giri","year":"2021","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e20021","article-title":"Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access","volume":"40","author":"Kourelis","year":"2022","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8042","article-title":"Idecabtagene vicleucel (ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): Real-world experience","volume":"40","author":"Hansen","year":"2022","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/S2152-2650(22)00336-6","article-title":"P-006: Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"22","author":"Canonico","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147990","article-title":"Subsequent anti-myeloma therapy after idecabtagene vicleucel (ide-cel, bb2121) treatment in patients with relapsed\/refractory multiple myeloma from the KarMMa study","volume":"138","author":"Rodriguez-Otero","year":"2021","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150592","article-title":"Anakinra targeting cytokine release syndrome associated with chimeric antigen receptor t-cell therapies","volume":"138","author":"Wong","year":"2021","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8028","article-title":"Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2","volume":"39","author":"Einsele","year":"2021","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"Suppl. 265","DOI":"10.57187\/smw.2022.40034","article-title":"Single-center experience with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma","volume":"152","author":"Akhoundova Sanoyan","year":"2022","journal-title":"Swiss Med Wkly"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012470","article-title":"Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma","volume":"8","author":"Mejia Saldarriaga","year":"2024","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2022.08.002","article-title":"CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil","volume":"45","author":"Hungria","year":"2022","journal-title":"Hematol Transfus Cell Ther"},{"key":"B39","unstructured":"The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.479","article-title":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment","volume":"3","author":"Abecassis","year":"2022","journal-title":"EJHaem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.014","article-title":"Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable","volume":"24","author":"Ailawadhi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.968","article-title":"A phase 1b\/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma","volume":"5","author":"Knop","year":"2024","journal-title":"EJHaem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24351","article-title":"Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(\u00ae) protein MP0250: a preclinical study","volume":"9","author":"Rao","year":"2018","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: How to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.51936\/fcfm6982","article-title":"Delphi method: strengths and weaknesses","volume":"16","author":"Fink-Hafner","year":"2019","journal-title":"Adv Methodol Stat"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1535869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:38:36Z","timestamp":1737448716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1535869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":45,"alternative-id":["10.3389\/fonc.2024.1535869"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1535869","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"article-number":"1535869"}}